

ABSTRACT

The present invention provides nitrogen-containing fused cyclic derivatives represented by the following general formula

5 or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance,

10 diabetic complications or obesity, in the formula one of R^1 and R^4 represents a group represented by the following general formula (S) (in which R^5 and R^6 represent H, OH, a halogen atom, etc.; Q represents an alkylene group etc.; and ring A represents an aryl group etc.), and the other represents H, OH, an amino

15 group, etc.; R^2 and R^3 represent H, OH, an amino group, a halogen atom, and an optionally substituted alkyl group, etc.; A^1 represents O, S, etc.; A^2 represents CH or N; G represents a group represented by the following general formula (G-1) or (G-2) (E^1 represents H, F or OH; and E^2 represents H, F, a methyl group, etc.), and pharmaceutical compositions comprising the same, and

20 pharmaceutical uses thereof.



